Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available on NHS

The drug developer expects its top line to benefit from the decision from 2019 and beyond
cholesterol
Homozygous Familial Hypercholesterolaemia is an inherited condition which causes abnormally high levels of ‘bad’ cholesterol

Amryt Pharma PLC’s (LON:AMYT) Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England.

HoFH is a rare life-threatening disorder that causes abnormally high levels of low density lipoprotein (LDL) cholesterol.

Clinical trials showed Lojuxta can reduce the production and uptake of this ‘bad’ cholesterol, helping sufferers to get their cholesterol levels down to acceptable levels.

Amryt expects the treatment to be available to HoFH patients treated by NHS England during the fourth quarter of 2018.

Earnings impact

“We are delighted that NHS England has recognised the significant unmet need in the current treatment of HoFH in England and the potential Lojuxta has to significantly improve the lives of HoFH patients,” said chief executive Joe Wiley.

“This decision today is in line with our strategy to make Lojuxta available to more patients across Amryt's territories and it is estimated that funding approval will have a positive impact on revenue from 2019 and beyond.”

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use